Hong Kong Stock Market Movement | Keji Pharmaceutical-B plunges more than 16%, with a 23-year loss of 748 million yuan, narrowing by 16.19% year-on-year
Koji Pharmaceutical-B plummeted by over 16%, closing at a 16.78% decrease to HKD 4.77 with a turnover of HKD 4.3 million. In terms of performance, as of the fiscal year ending December 31, 2023, the group incurred R&D expenses of RMB 662 million, a decrease of 2.74% year-on-year; shareholders' attributable loss was RMB 748 million, narrowing by 16.19% year-on-year; basic loss per share was RMB 1.34. The announcement stated that the main reason for the narrowing loss was the reduction in share-based compensation. Previously, the company announced that the board of directors declared that the summary of CT041 (a targeted Claudin18.2 autologous CAR-T cell candidate product) has been accepted for oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. It is reported that CT041 is a potential globally pioneering autologous CAR-T cell candidate product targeting the Claudin18.2 protein, used to treat Claudin18.2-positive solid tumors, mainly for the treatment of gastric/esophagogastric junction adenocarcinoma and pancreatic cancer
According to the Zhitong Finance and Economics APP, Keji Pharmaceutical-B (02171) plummeted by over 16%, dropping by 16.78% to HKD 4.77 with a turnover of HKD 4.3 million as of the time of publication.
In terms of performance, for the fiscal year ending on December 31, 2023, the group incurred R&D expenses of RMB 662 million, a decrease of 2.74% year-on-year. Shareholders' attributable loss was RMB 748 million, narrowing by 16.19% year-on-year. Basic loss per share was RMB 1.34. The announcement stated that the main reason for the narrowing loss was the reduction in share-based compensation.
Previously, the company announced that the Board of Directors declared that the abstract of CT041 (a targeted Claudin18.2 autologous CAR-T cell candidate product) has been accepted for oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. It is reported that CT041 is a potential globally pioneering autologous CAR-T cell candidate product targeting the Claudin18.2 protein, used to treat Claudin18.2-positive solid tumors, primarily for the treatment of gastric/esophagogastric junction adenocarcinoma and pancreatic cancer